Autopsy report · NCT02702115
Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I
Cause of deathOther
“All three subjects dosed in the study have rolled over to the Long-Term Follow-up Study IVPRP-LT01 (NCT04628871)”
Life of this trial
- Registered 1 year 3 months before it started.
- Ran for about 4 years 5 months before it stopped.
- 3 participants enrolled.
- Results were posted on the registry 1 year 3 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Sangamo Therapeutics
- Sponsor type
- Industry
- Conditions
- MPS I
- Interventions
- SB-318
- Participants
- 3
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Fecal Transplant for MDR Pathogen Decolonization
“This observational study has been transitioned to a clinical trial and is now registered at (NCT04181112).” - Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease
“Per protocol, 3 sequential dose cohorts were planned. Study discontinued by Sponsor based upon serious adverse events in first 2 of 3 participants in Cohort 1.” - An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders
“all active subjects were rolled into study 209AS209/NCT01706523” - Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients
“The study has been prematurely terminated due to the onset of 2 dose limiting toxicities in 2 patients.” - Vaping High vs. Low Nicotine E-Liquid
“Please see NCT04053868 for the current version of this study”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.